5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management [PDF]
MedicinaBackground and Objectives: Benign prostatic hyperplasia (BPH) is a progressive, androgen-dependent condition driven by dihydrotestosterone (DHT). 5α-reductase inhibitors (5-ARIs), including finasteride and dutasteride, target this pathway and provide ...
Christos Roidos +4 more
doaj +2 more sources
Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance [PDF]
Urology Research and Practice, 2019 Objective: The incidence of prostate adenocarcinoma (PCa) is increased with the use of prostate-specific antigen (PSA). In the current study, we aimed to investigate the impact of 5- alpha- reductase inhibitors (5-ARI) on pathological progression in ...
Tayyar Alp Özkan +3 more
doaj +2 more sources
Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection [PDF]
BiomoleculesConcerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection.
Juan Morote +10 more
doaj +2 more sources
Management of patients with lower urinary tract symptoms due to benign prostatic enlargement at risk of progression treated with 5-alpha-reductase inhibitors: examining real-world clinical practice in Spain and Brazil [PDF]
BMC UrologyBackground For patients with lower urinary tract symptoms due to benign prostatic enlargement (LUTS/BPE), assessing patient risk of disease progression is important to determine if treatment with 5-alpha-reductase inhibitors (5ARIs) is warranted ...
Juan Manuel Palacios +7 more
doaj +2 more sources
The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study [PDF]
The World Journal of Men's HealthPurpose: To investigate the long-term effects of taking 5-alpha reductase inhibitors (5ARIs) on the development of bladder cancer (BC) and the implementation of radical cystectomy (RC), a standard procedure for advanced BC.
Jong Hyun Pyun +5 more
doaj +2 more sources
5-alpha Reductase inhibitors and risk of male breast cancer: a systematic review and meta-analysis [PDF]
International Brazilian Journal of Urology, 2018 Objective: To assess the relationship between 5α-reductase inhibitors (5ARIs) and the risk of male breast cancer (MBC). Material and Methods: We systematically searched Medline via PubMed, Embase and the Cochrane Library Central Register up to May 2017 ...
Jiamin Wang +5 more
doaj +2 more sources
High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia [PDF]
Journal of Urology, 2020 Aria Olumi +2 more
exaly +2 more sources
Risk of estrogen-driven malignancies in females on 5-alpha reductase inhibitors
Archives of Dermatological ResearchAbstract Importance: It is hypothesized that 5α-reductase inhibitors (5aRI) increase aromatase-mediated conversion of testosterone to estrogen, which may facilitate development of estrogen-driven malignancy. Previous studies in male patients receiving 5aRI treatment failed to demonstrate an increased risk of breast cancer; however, similar ...
Thomas Z Rohan
exaly +3 more sources
Post-finasteride syndrome, [PDF]
Anais Brasileiros de Dermatologia, 2020 Finasteride is a 5α-reductase enzyme inhibitor that has been approved for the treatment of male androgenic alopecia since 1997. Over time, it has been considered a safe and well-tolerated drug with rare and reversible side effects.
Ana Francisca Junqueira Ribeiro Pereira +1 more
doaj +1 more source
Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. [PDF]
PLoS ONE, 2015 This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan.In total, 1 ...
Teng-Fu Hsieh +8 more
doaj +1 more source